These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21722151)

  • 1. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly.
    Fougner SL; Casar-Borota O; Heck A; Berg JP; Bollerslev J
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):96-102. PubMed ID: 21722151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.
    Fougner SL; Borota OC; Berg JP; Hald JK; Ramm-Pettersen J; Bollerslev J
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):458-65. PubMed ID: 17941904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.
    Larkin S; Reddy R; Karavitaki N; Cudlip S; Wass J; Ansorge O
    Eur J Endocrinol; 2013 Apr; 168(4):491-9. PubMed ID: 23288882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response.
    Fougner SL; Lekva T; Borota OC; Hald JK; Bollerslev J; Berg JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2334-42. PubMed ID: 20335450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
    Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
    Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
    Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
    Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
    Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-cadherin expression is associated with somatostatin analogue response in acromegaly.
    Venegas-Moreno E; Flores-Martinez A; Dios E; Vazquez-Borrego MC; Ibañez-Costa A; Madrazo-Atutxa A; Japón MA; Castaño JP; Luque RM; Cano DA; Soto-Moreno A
    J Cell Mol Med; 2019 May; 23(5):3088-3096. PubMed ID: 30843342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.
    Obari A; Sano T; Ohyama K; Kudo E; Qian ZR; Yoneda A; Rayhan N; Mustafizur Rahman M; Yamada S
    Endocr Pathol; 2008; 19(2):82-91. PubMed ID: 18629656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.
    Swanson AA; Erickson D; Donegan DM; Jenkins SM; Van Gompel JJ; Atkinson JLD; Erickson BJ; Giannini C
    Pituitary; 2021 Apr; 24(2):192-206. PubMed ID: 33074402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas.
    Kato M; Inoshita N; Sugiyama T; Tani Y; Shichiri M; Sano T; Yamada S; Hirata Y
    Endocr J; 2012; 59(3):221-8. PubMed ID: 22200580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
    Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
    Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.
    Heck A; Emblem KE; Casar-Borota O; Bollerslev J; Ringstad G
    Endocrine; 2016 May; 52(2):333-43. PubMed ID: 26475495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin.
    Gliga MC; Chinezu L; Pascanu IM
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.
    Soukup J; Hornychova H; Manethova M; Michalova K; Michnova L; Popovska L; Skarkova V; Cesak T; Netuka D; Ryska A; Cap J; Hána V; Hána V; Kršek M; Dvořáková E; Krčma M; Lazurova I; Olšovská V; Starý K; Vaňuga P; Gabalec F
    J Cell Mol Med; 2021 Mar; 25(5):2484-2492. PubMed ID: 33491286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas.
    Petersenn S; Heyens M; Lüdecke DK; Beil FU; Schulte HM
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):35-42. PubMed ID: 10651751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.
    Casar-Borota O; Heck A; Schulz S; Nesland JM; Ramm-Pettersen J; Lekva T; Alafuzoff I; Bollerslev J
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1730-9. PubMed ID: 24092823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.
    Kiseljak-Vassiliades K; Xu M; Mills TS; Smith EE; Silveira LJ; Lillehei KO; Kerr JM; Kleinschmidt-DeMasters BK; Wierman ME
    Mol Cell Endocrinol; 2015 Dec; 417():73-83. PubMed ID: 26391562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.
    Lee CC; Vance ML; Lopes MB; Xu Z; Chen CJ; Sheehan J
    Pituitary; 2015 Jun; 18(3):326-34. PubMed ID: 24925503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.